Phase II High-Dose Cyclophosphamide for Multiple Sclerosis

Phase 2 Withdrawn 25 enrolled Stony Brook University

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine what percentage of patients receiving high-dose Cyclophosphamide may experience a halt in the worsening of their disease or experience improvement of their disease and for how long the benefit may last.

Timeline

Start: 2003-10
Primary completion: —
Completion: 2006-02

Outcome

Outcome not reported

Stopped: “I am changing locations to Johns Hopkins Medical Center”

Publications

Results Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol. 2006 Oct;63(10):1388-93. doi: 10.1001/archneur.63.10.noc60076. Epub 2006 Aug 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	200 mg/kg	—